Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Femasys (FEMY)
NASDAQ:FEMY
Femasys (FEMY) Stock Price & Analysis
288 Followers
FEMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.25 - $4.75
Previous Close$1.1
Volume93.77K
Average Volume (3M)211.22K
Market Cap
$24.44M
Enterprise Value$11.08M
Total Cash (Recent Filing)$17.84M
Total Debt (Recent Filing)$4.47M
Price to Earnings (P/E)―
Beta-0.75
Next Earnings
Aug 07, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding22,220,718
10 Day Avg. Volume308,450
30 Day Avg. Volume211,218
Standard Deviation1.03
R-Squared0.02
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)1.64
Price to Sales (P/S)23.84
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.80
Enterprise Value/Gross Profit16.01
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$9.00Price Target Upside710.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Femasys News
Bulls Say, Bears Say
Bulls Say
Commercial LaunchThe commercial launch of the company's infertility treatment, FemaSeed, is underway.
EfficacyFemaSeed obtained FDA 510(k) clearance and has demonstrated a 24% pregnancy rate in its pivotal study.
Market PotentialMale factor infertility is a significant contributor to infertility, affecting up to 50% of infertile couples, indicating a large target market for FemaSeed.
Bears Say
EarningsFemasys reported 1Q24 results with revenue of $0.3M and a net loss of ($3.6M).
EarningsFemasys filed its 10-K, reporting revenue of $1M and a net loss of ($14.2M).
Financial PerformanceEstimates for FemaSeed revenue in 2024 and 2025 have been lowered.
---
Ownership Overview
8.00%
Insiders
2.11% Mutual Funds
4.48% Other Institutional Investors
85.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $0.25 and its highest was $4.75 in the past 12 months.
What is Femasys’s market cap?
Currently, no data Available
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Aug 07, 2024 which is in 32 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on May 09, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.02.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -$0.16.
How many shares outstanding does Femasys have?
Femasys has 22,220,718 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -8.633%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
---
Femasys Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (710.81% Upside)
$9.00 (710.81% Upside)
Blogger Sentiment
Bullish
FEMY Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.57%
12-Months-Change
Fundamentals
Return on Equity
-106.57%
Trailing 12-Months
Asset Growth
75.74%
Trailing 12-Months
Company Description
Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
---
FEMY Stock 12 Month Forecast
Average Price Target
$9.00
▲(710.81% Upside)
Technical Analysis
Best Analysts Covering FEMY
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+24.77%
reiterated a buy rating 8 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +24.77% per trade.
---